RecruitingEarly Phase 1NCT03537482

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies

Sponsor

Ascentage Pharma Group Inc.

Enrollment

90 participants

Start Date

Aug 7, 2018

Study Type

INTERVENTIONAL

Conditions

Hematologic Malignancies

Summary

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Eligibility

Min Age: 18 Years

Inclusion Criteria12

Age ≥18 years old.
Histologically confirmed diagnosis of either one of the B-cell hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and non-Hodgkin's lymphoma such as mantle cell lymphoma, diffuse large B cell lymphoma, Waldenstrom macroglobulinemia (WM) and acute myeloid leukemia
Patient must have relapsed or refractory to, intolerant to, or are considered ineligible for therapies known to provide clinical benefit. In addition,
a. AML Patients will be eligible if they have failed standard induction regimen, are not considered candidate for further chemotherapy or stem cell transplantation or have primary refractory AML.
Life expectancy ≥ 3 months.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1 in dose escalation ; 0-2 in dose expansion.
QTc interval ≤450ms in males, and ≤470ms in females.
Adequate bone marrow function independent of growth factor:
Absolute neutrophil count (ANC) ≥1.0 X 109/L.
Hemoglobin ≥ 8.0 g/dL.
Platelets count ≥ 30 X 109/L (entry platelet count must be independent of transfusion within 7 days of first dose).
Adequate renal and liver function as indicated by:

Exclusion Criteria13

Prior history of allogeneic cell transplant.
Subjects have been diagnosed with Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.
Received chemotherapy within 14 days (42 days for nitrosoureas or mitomycin C) prior to entering the study.
Received biologic (< 28 days), small molecule targeted therapies (< 5 half-life) or other anti-cancer therapy within 21 days of study entry.
Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry.
Has gastrointestinal conditions that could affect the absorption of APG-2575 in the opinion of the Investigator.
Has known active central nervous system (CNS) involvement.
Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia or neuropathy.
Concurrent treatment with an investigational agent, 14 days for small molecular agents and/or 28 days for biologics treatment prior to the first dose of therapy.
Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry.
Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation.
Active infection requiring systemic antibiotic/ antifungal medication, known clinically active hepatitis B or C infection, or on antiretroviral therapy for HIV disease.